Fundraising Fox
/Companies
Sign in

Abbratech Inc.

Branford, US · 2 known investors

Find your way into Abbratech Inc.

Sign up to see every warm intro you have to Abbratech Inc.

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Abbratech Inc. team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

AbbraTech develops a platform technology for the discovery, engineering, and validation of antibodies, targeting disease-relevant proteins that are difficult to address with conventional approaches. It works with industry and academic partners to develop antibody therapies for conditions such as cancer, immune disorders, and viral infections.

BiotechDeep Tech

Founders & leadership

MWMichael Weiner
Michael WeinerFounderMichael Weiner holds a Ph.D. in Genetics from Cornell University and has founded multiple life sciences companies including Affomix, AxioMx, GnuBio, Encodia, and Abbratech, where he serves as Founder and CEO developing antibody discovery and engineering platform technologies. He has held senior scientific roles at 454 Life Sciences and RainDance Technologies, authored numerous peer-reviewed publications, holds multiple patents in genomics and proteomics, and has received substantial NIH and DARPA research funding.

Investors · 2

Elm Street Ventureslisted by Elm Street VenturesNew Haven · $250K – $1M

How we know: Elm Street Ventures's portfolio page · Not right? Tell us

Related companies · 2

AbcamSupplier of protein research tools to life scientists. Publicly listed on the LSE following an IPO.
Triple Ring Technologies

Companies working in the same space as Abbratech Inc..

Non-dilutive funding · 6 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2023$1.1M
National Institutes of Health (NIH)National Institutes of HealthPhase II2023$1.1M
National Institutes of Health (NIH)National Institutes of HealthPhase I2023$296.1K
National Institutes of Health (NIH)National Institutes of HealthPhase I2023$295.5K
National Institutes of Health (NIH)National Institutes of HealthPhase I2022$339.1K
National Institutes of Health (NIH)National Institutes of HealthPhase I2022$253.4K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Abbratech Inc. do?
AbbraTech develops a platform technology for the discovery, engineering, and validation of antibodies, targeting disease-relevant proteins that are difficult to address with conventional approaches. It works with industry and academic partners to develop antibody therapies for conditions such as cancer, immune disorders, and viral infections.
Who founded Abbratech Inc.?
Abbratech Inc. was founded by Michael Weiner.
Who are Abbratech Inc.'s investors?
Abbratech Inc.'s investors include Connecticut Innovations, Elm Street Ventures.
Where is Abbratech Inc. headquartered?
Abbratech Inc. is headquartered in Branford, US.